A Phase II clinical trial of VM202 in subjects with Amyotrophic Lateral Sclerosis (AML)

Trial Profile

A Phase II clinical trial of VM202 in subjects with Amyotrophic Lateral Sclerosis (AML)

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 New trial record
    • 09 Feb 2017 According to VM BioPharma media release, the Company has obtained Investigational New Drug (IND) approval from the FDA for a Phase 2 clinical trial of VM202 for ALS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top